HIV therapy by a combination of broadly neutralizing antibodies in humanized mice

F Klein, A Halper-Stromberg, JA Horwitz, H Gruell… - Nature, 2012 - nature.com
F Klein, A Halper-Stromberg, JA Horwitz, H Gruell, JF Scheid, S Bournazos, H Mouquet…
Nature, 2012nature.com
Human antibodies to human immunodeficiency virus-1 (HIV-1) can neutralize a broad range
of viral isolates in vitro and protect non-human primates against infection,. Previous work
showed that antibodies exert selective pressure on the virus but escape variants emerge
within a short period of time,. However, these experiments were performed before the recent
discovery of more potent anti-HIV-1 antibodies and their improvement by structure-based
design,,,,. Here we re-examine passive antibody transfer as a therapeutic modality in HIV-1 …
Abstract
Human antibodies to human immunodeficiency virus-1 (HIV-1) can neutralize a broad range of viral isolates in vitro and protect non-human primates against infection,. Previous work showed that antibodies exert selective pressure on the virus but escape variants emerge within a short period of time,. However, these experiments were performed before the recent discovery of more potent anti-HIV-1 antibodies and their improvement by structure-based design,,,,. Here we re-examine passive antibody transfer as a therapeutic modality in HIV-1-infected humanized mice. Although HIV-1 can escape from antibody monotherapy, combinations of broadly neutralizing antibodies can effectively control HIV-1 infection and suppress viral load to levels below detection. Moreover, in contrast to antiretroviral therapy,,, the longer half-life of antibodies led to control of viraemia for an average of 60 days after cessation of therapy. Thus, combinations of potent monoclonal antibodies can effectively control HIV-1 replication in humanized mice, and should be re-examined as a therapeutic modality in HIV-1-infected individuals.
nature.com